Daily Updates
Iovance Fell 35% After Its Lung Cancer Data Matched Last Year’s
Iovance fell 35.4% on October 29, 2026 after lifileucel’s 24.6% lung cancer response rate matched last year’s interim and it pivoted to biomarker selection.
Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Iovance fell 35.4% on October 29, 2026 after lifileucel’s 24.6% lung cancer response rate matched last year’s interim and it pivoted to biomarker selection.
Lilly’s retatrutide cut A1C by 2.2 points and weight by 20.9% against Ozempic’s 1.8 and 9.4% in the TRANSCEND-T2D-2 trial reported October 28, 2026.
Artiva ended its AlloNK autoimmune cell therapy on October 27, 2026 after two patient deaths, cutting 94% of staff and weighing a sale or wind down.
Merck’s sac-TMT cut the risk of death 32% in previously treated endometrial cancer at ESMO on October 26, 2026, and the FDA set its decision for June 15, 2027.
Imdelltra plus Imfinzi cut first line small cell lung cancer death risk 58% at ESMO on October 24, 2026, with median survival of 21.1 versus 12.7 months.
Treasury proposed adding biotech to US outbound investment rules on October 22, 2026, six days after China moved to wall off its own biotech platforms.
Abbott said on October 21, 2026 it will spin off its $8.5 billion Nutrition business into an independent company by the end of 2027 and tightened EPS guidance.
The FDA approved GSK’s Hibsago (bepirovirsen) for chronic hepatitis B on October 20, 2026, with a 19 percent functional cure rate in the B-Well Phase 3 program.
Roche agreed on October 19, 2026 to pay Hansoh Pharma $400 million upfront and over $15 billion in potential milestones for ADCs built on its platform.
Medtronic Completed the MiniMed Separation as China Proposed Export Bans on Biotech Platforms and City Therapeutics Debuted Up 24.4%, October 19, 2026 Last updated: October